These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17004081)

  • 1. [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease].
    Dengler I; Leukel N; Meuser T; Jost WH
    Nervenarzt; 2006 Oct; 77(10):1204-9. PubMed ID: 17004081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs].
    Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH
    Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
    Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of illness and its predictors for Parkinson's disease in Germany.
    Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
    Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of direct costs in therapy of Parkinson disease].
    Keller S; Kessler T; Meuser T; Fogel W; Bremen D; Jost WH
    Nervenarzt; 2003 Dec; 74(12):1105-9. PubMed ID: 14647911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct costs of managing Parkinson's disease in India: concerns in a developing country.
    Ragothaman M; Govindappa ST; Rattihalli R; Subbakrishna DK; Muthane UB
    Mov Disord; 2006 Oct; 21(10):1755-8. PubMed ID: 16874759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indirect costs in idiopathic Parkinson's disease].
    Barth F; Baum B; Bremen D; Meuser T; Jost WH
    Fortschr Neurol Psychiatr; 2005 Apr; 73(4):187-91. PubMed ID: 15806436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost of care for depressive disorders in primary and specialized care in Germany].
    Salize HJ; Stamm K; Schubert M; Bergmann F; Härter M; Berger M; Gaebel W; Schneider F
    Psychiatr Prax; 2004 Apr; 31(3):147-56. PubMed ID: 15042478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug costs for patients with Parkinson's disease in two different European countries.
    Vossius C; Gjerstad M; Baas H; Larsen JP
    Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health insurance expenses for children in the first five years of life - a cohort-based analysis].
    Reichert J; Schemken M; Manthei R; Steinbronn R; Bucher U; Albrecht M; Rüdiger M
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):451-60. PubMed ID: 24238022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
    Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
    CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Costs and benefits of an education program for patients with ankylosing spondylitis as part of an inpatient rehabilitation programs-study design and first results].
    Krauth C; Rieger J; Bönisch A; Ehlebracht-König I
    Z Rheumatol; 2003; 62(Suppl 2):II14-6. PubMed ID: 14648082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in resource utilization for Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
    J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom.
    Findley L; Aujla M; Bain PG; Baker M; Beech C; Bowman C; Holmes J; Kingdom WK; MacMahon DG; Peto V; Playfer JR
    Mov Disord; 2003 Oct; 18(10):1139-45. PubMed ID: 14534917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
    Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
    Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.